BenchSci, a provider of AI solutions for preclinical research and drug discovery, announced a strategic partnership with Thermo Fisher Scientific on September 30th. The partnership will see Thermo Fisher implement BenchSci’s ASCEND AI technology to create new tools to accelerate experimental design and improve R&D productivity.

According to a company press release, Thermo Fisher will use the ASCEND technology, a scalable AI assistant for preclinical organizations, to develop new AI-enabled tools. This includes enterprise software solutions for scientific and analytical instruments, advanced web-based research literature search, and optimized reagent selection.

“BenchSci’s technology acts as an AI assistant for scientists, leveraging a proprietary biomedical knowledge graph and machine learning models to decode scientific evidence and uncover biological insights. This partnership will expand what’s possible for researchers everywhere,” said Liran Belenzon, CEO and co-founder, BenchSci, in the release. “Pairing our AI expertise with Thermo Fisher’s footprint of lab equipment, consumables, and services will create new opportunities for scientists across the life sciences ecosystem.”

“AI is unlocking a new era of scientific possibility, and our partnership with BenchSci will help our customers accelerate their important work,” said Gianluca Pettiti, executive VP and president, Life Sciences, Diagnostics and Applied, Thermo Fisher Scientific, in the release. “By combining our global scale, world-class products, and innovation leadership with BenchSci’s advanced AI capabilities, we will transform our customers’ capabilities to model science in silico, enabling them to move from scientific ideas to approved medicines faster and more cost-effectively.”